Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …

Lung cancer is the leading cause of cancer death in Canada and a significant cause of
morbidity for patients and their loved ones. There have been rapid advances in preventing …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …